首页> 外文期刊>Modern Pathology >Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness
【24h】

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness

机译:细胞周期调节剂表达对膀胱癌发展和生物侵袭性的合作效应

获取原文

摘要

The aim of this study was to evaluate the association between p53, p21, p27 and Rb expression, alone or in combination, with pathological features and clinical outcomes of urothelial carcinoma of the bladder. Immunohistochemical staining for p53, p21, p27 and pRB was performed on tissue microarrays comprising normal urothelium from nine controls, transurethral resection specimens from 74 patients with Ta, Tis and/or T1 bladder urothelial carcinoma, radical cystectomy specimens from 226 consecutive urothelial carcinoma patients, and lymph nodes with tumor invasion from 50 of the 226 cystectomy patients. All nine controls had normal status of biomarkers. The proportion of biomarkers alterations was highest in lymph node metastases. p53, pRB and p27 were associated with pathologic stage, lymphovascular invasion and lymph node metastases (P-values0.050). Each biomarker alone, each combination of two biomarkers and the number of altered biomarkers were all independently associated with disease recurrence and bladder cancer-specific death (P-values0.046). In patients with organ-confined disease, p53, p21 and p27 were independently associated with disease recurrence and bladder cancer-specific death (P-values0.046). There was a good but not perfect concordance in the expression of biomarkers between matched transurethral resection and cystectomy specimens (n=22; concordance rates: 77–86%) and between matched lymph node and cystectomy specimens (n=50, 70–92%). In conclusion, p53, p21, p27 and pRB have a cooperative/synergistic role in the biologic behavior of bladder urothelial carcinoma. In contrast to the use of single biological markers, evaluation of their combined status may improve prognostic models and help identify patients who might benefit from adjuvant therapies and in decision-making.
机译:本研究的目的是评估P53,P21,P27和RB表达,单独或组合之间的关联,具有膀胱尿路皮癌的病理特征和临床结果。对P53,P21,P27和PRB的免疫组织化学染色在组织微阵列上进行了来自九种对照的常规尿素,经尿道ral术分解试样,来自74例TA,TIS和/或T1膀胱尿路上皮癌,自由基膀胱切除术患者,自由基膀胱切除术患者,和淋巴结从226例膀胱切除术患者中的50个患有肿瘤侵袭。所有九个控制都有正常的生物标志物状况。淋巴结转移中的生物标志物改变的比例最高。 P53,PRB和P27与病理阶段,淋巴血管侵袭和淋巴结转移相关(P值0.050)。单独的每种生物标志物,每种生物标志物的每种组合和改变的生物标志物的数量都与疾病复发和膀胱癌特异性死亡(P值0.046)独立相关。在有器官局限性疾病的患者中,P53,P21和P27与疾病复发和膀胱癌特异性死亡(P值0.046)独立相关。在匹配的经尿道切除和膀胱切除术标本(n = 22;一致性率:77-86 %)和匹配的淋巴结和膀胱切除术样品之间(n = 50,70-92之间的生物标志物的表达%)。总之,P53,P21,P27和PRB在膀胱尿路上皮癌的生物学行为中具有合作/协同作用。与使用单一生物标记物的使用相比,它们的组合地位的评估可以改善预后模型,并帮助识别可能从佐剂疗法和决策中受益的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号